Wedbush Forecasts Strong Price Appreciation for Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics (NASDAQ:VERA) had its price objective upped by Wedbush from $35.00 to $43.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Wedbush’s price target points to a potential upside of 0.09% from the stock’s previous close.

A number of other equities analysts also recently issued reports on VERA. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Monday, April 20th. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. Evercore set a $91.00 target price on Vera Therapeutics in a research note on Friday, May 15th. Wolfe Research raised shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target on the stock in a research note on Wednesday, March 11th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $60.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Vera Therapeutics has an average rating of “Moderate Buy” and an average price target of $80.90.

Vera Therapeutics Stock Up 7.1%

Shares of VERA stock opened at $42.96 on Wednesday. Vera Therapeutics has a fifty-two week low of $19.07 and a fifty-two week high of $56.05. The firm has a market capitalization of $3.08 billion, a PE ratio of -7.75 and a beta of 0.92. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. The stock’s 50-day simple moving average is $36.29 and its 200-day simple moving average is $41.20.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the previous year, the firm earned ($0.81) EPS. Equities analysts expect that Vera Therapeutics will post -6.23 earnings per share for the current year.

Insiders Place Their Bets

In other news, CEO Marshall Fordyce sold 22,951 shares of the business’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55. Following the transaction, the chief executive officer directly owned 235,244 shares in the company, valued at $10,362,498.20. The trade was a 8.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 59,951 shares of company stock valued at $2,392,387. Company insiders own 15.90% of the company’s stock.

Institutional Trading of Vera Therapeutics

Several institutional investors have recently made changes to their positions in VERA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Vera Therapeutics by 7.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock valued at $753,000 after buying an additional 2,210 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Vera Therapeutics by 22.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock worth $2,354,000 after acquiring an additional 17,907 shares during the last quarter. Jane Street Group LLC boosted its position in shares of Vera Therapeutics by 297.1% during the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock worth $999,000 after purchasing an additional 62,678 shares during the period. JPMorgan Chase & Co. increased its holdings in Vera Therapeutics by 550.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock valued at $7,316,000 after purchasing an additional 262,805 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in Vera Therapeutics by 1.7% in the 2nd quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock valued at $1,188,000 after purchasing an additional 825 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Key Vera Therapeutics News

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: Vera Therapeutics received FDA accelerated approval for TRUTAKNA in adult patients with primary IgA nephropathy, a major regulatory milestone that can unlock initial revenue and validate the company’s lead program. Article Title
• Positive Sentiment: HC Wainwright raised its price target on Vera Therapeutics from $110 to $125 and reiterated a buy rating, signaling increased optimism after the approval. Article Title
• Positive Sentiment: Bank of America also lifted its price target from $65 to $70 and kept a buy rating, reinforcing bullish analyst sentiment around the FDA win. Article Title
• Positive Sentiment: Multiple reports noted the stock surged after the FDA decision, suggesting investors see the approval as a key catalyst for future growth. Article Title

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.